Cancer clinical trials in the region Nouvelle-Aquitaine

454 currently recruiting clinical trials
Region Nouvelle-Aquitaine
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Required HER2 statuses
HER2 Positive
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy Bispecific T-cell engager antibodies Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lung cancer #NCT04939610 #2023-508995-12-01
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer #NCT04939610 #2023-508995-12-01
Cancer du sein triple négatif TNBC Monotherapie
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Pancreas cancer #NCT04939610 #2023-508995-12-01
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04939610 #2023-508995-12-01
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors Skin cancer #NCT05768139 #2023-000442-41
Required histologic types
Oral cavity Nasopharynx Oropharynx Hypopharynx Larynx Nasal cavities and sinuses
Required histologic sub types
Squamous cell carcinoma
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
PIK3CA
Required number of previous lines of therapy
1 2 3 or more
6 recruiting sites
Eli Lilly et compagnie
Phase 1 / Phase 2 Prostate cancer #NCT04104776 #2023-508002-20-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic Castration-resistant
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Hormone therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Bladder / Urinary Tract / Urethral cancer #NCT04104776 #2023-508002-20-00
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Endometrial cancer #NCT04104776 #2023-508002-20-00
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ARID1A
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals
Phase 1 / Phase 2 Lung cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04104776 #2023-508002-20-00
Required histologic types
Mesothelium Primary peritoneal cancer (PPC)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Other mutation
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Novartis Pharmaceuticals